Diabetes May Short Circuit Pembrolizumab Benefits in NSCLC Diabetes May Short Circuit Pembrolizumab Benefits in NSCLC
The new study shows a correlation between diabetes and poor outcomes for patients with metastatic non –small cell lung cancer (NSCLC) who received pembrolizumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III …
(Source: Reuters: Health)
Source: Reuters: Health - July 3, 2023 Category: Consumer Health News Source Type: news
AstraZeneca shares fall after cancer drug trial disappoints investors
Trial studied patients with advanced non-small cell lung cancer (Source: Reuters: Health)
Source: Reuters: Health - July 3, 2023 Category: Consumer Health News Source Type: news
Key Data on Advanced NSCLC From ASCO 2023 Key Data on Advanced NSCLC From ASCO 2023
Data from KEYNOTE-789, plus results on the EGFR exon 20 inhibitor sunvozertinib and a promising sotorasib combination for KRAS G12C-mutant disease, are highlights in advanced NSCLC from ASCO 2023.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
Efficacy of Therapies for Brain Metastases of NSCLC Efficacy of Therapies for Brain Metastases of NSCLC
There are a number of available treatment options for NSCLC patients with brain metastases. Which is the most effective strategy?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Alectinib Exposure Lower With Low-Fat Yogurt Intake
WEDNESDAY, June 14, 2023 -- For patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer, alectinib exposure is lower when taken with low-fat yogurt, according to a study published in the June issue of the Journal of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2023 Category: Pharmaceuticals Source Type: news
TTFields Therapy Yields OS Improvement in Second-Line NSCLC
(MedPage Today) -- CHICAGO -- Treatment with tumor treating field (TTFields) therapy combined with standard of care improved overall survival versus standard of care alone in patients with metastatic non-small cell lung cancer (NSCLC) who have... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 8, 2023 Category: Hematology Source Type: news
Biden ’s FTC is blocking a game-changer for cancer patients
Seventy years ago, Dr. Jonas Salk announced to an astonished radio audience he had developed a polio vaccine. It must have seemed too good to be true. The year before, polio claimed 3,000 American lives and infected another 60,000. Millions lived in fear of contracting the incurable disease.…#jonassalk #linakhan #grail #illumina #edison #avalerehealth #medicare #nsclc #ftc (Source: Reuters: Health)
Source: Reuters: Health - June 8, 2023 Category: Consumer Health News Source Type: news
Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC
(MedPage Today) -- CHICAGO -- In patients with metastatic EGFR-positive lung cancer who progressed on targeted agents, adding pembrolizumab (Keytruda) to a standard chemotherapy regimen demonstrated no survival benefit, a randomized trial found... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 7, 2023 Category: Hematology Source Type: news
Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years
(MedPage Today) -- CHICAGO -- Patients with advanced non-small cell lung cancer (NSCLC) who are progression-free may discontinue treatment with frontline immunotherapy after 2 years without compromising overall survival (OS), a retrospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2023 Category: Hematology Source Type: news
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
TUESDAY, June 6, 2023 -- For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for two years, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2023 Category: Pharmaceuticals Source Type: news
New Data in NSCLC Bolster Support for Perioperative Immunotherapy
(MedPage Today) -- CHICAGO -- A randomized trial testing the addition of perioperative pembrolizumab (Keytruda) to chemotherapy in operable non-small cell lung cancer (NSCLC) hit one of its two primary endpoints in an interim analysis, with a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2023 Category: Hematology Source Type: news
Drug study offers hope for improved lung-cancer survival following surgery
A new Yale-led study finds improved survival rates and reduced risk of recurrence of non-small cell lung cancer with the drug osimertinib following surgery. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 5, 2023 Category: Universities & Medical Training Source Type: news
Drug study offers hope for improved lung-cancer survival after surgery
A new Yale-led study finds improved survival rates and reduced risk of recurrence of non-small cell lung cancer with the drug osimertinib following surgery. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 5, 2023 Category: Universities & Medical Training Source Type: news
Osimertinib improves survival after surgery for non-small cell lung cancer
A new Yale-led study finds improved survival rates and reduced risk of recurrence of non-small cell lung cancer with the drug osimertinib following surgery. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 5, 2023 Category: Universities & Medical Training Source Type: news
